Walleye Capital’s Aurinia Pharmaceuticals AUPH Stock Holding History

Walleye Capital’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$283K	Sell	16,700 -14,000	-46%	-$224K	﹤0.01%	3224
2026 Q1	$455K	Sell	30,700 -45,300	-60%	-$662K	﹤0.01%	2742
2025 Q4	$1.21M	Buy	76,000 +50,100	+193%	+$710K	﹤0.01%	2282
2025 Q3	$286K	Buy	25,900 +14,600	+129%	+$159K	﹤0.01%	3048
2025 Q2	$95.7K	Buy	11,300 +2,500	+28%	+$20K	﹤0.01%	3791
2025 Q1	$70.8K	Sell	8,800 -21,200	-71%	-$172K	﹤0.01%	3746
2024 Q4	$269K	Buy	30,000 +2,500	+9%	+$20.4K	﹤0.01%	3521
2024 Q3	$202K	Buy	+27,500	New	+$171K	﹤0.01%	4002
2024 Q2	–	Sell	-4,100	Closed	-$20.5K	–	5573
2024 Q1	$20.5K	Buy	+4,100	New	+$27.8K	﹤0.01%	4919
2023 Q1	–	Sell	-1,000	Closed	-$4.32K	–	3928
2022 Q4	$4.32K	Sell	1,000 -1,000	-50%	-$5.8K	﹤0.01%	2878
2022 Q3	$15K	Buy	+2,000	New	+$17.3K	﹤0.01%	2764

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Walleye Capital's AUPH Position: Q2 2026 in Review

Walleye Capital reduced its Aurinia Pharmaceuticals (AUPH) stake by 80% in Q2 2026, selling an estimated $4.09M and leaving 65,696 shares worth $1.11M. The position accounts for ﹤0.01% of the portfolio, ranked #2020.

Walleye Capital first reported a position in AUPH in Q4 2019 and has held it in 11 quarters since. The position peaked at $4.77M in Q1 2026. 282 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

Walleye Capital held 65,696 shares of Aurinia Pharmaceuticals worth $1.11M as of Q2 2026.
Walleye Capital sold 255,871 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $4.09M.
Aurinia Pharmaceuticals made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #2020 holding.
Walleye Capital first reported a position in Aurinia Pharmaceuticals in Q4 2019 and has held it in 11 quarters since.
Walleye Capital's Aurinia Pharmaceuticals position peaked at $4.77M in Q1 2026.
282 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.